A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
Takeda has suspended screening and further enrollment in the clinical studies of its AAV8 gene therapies for the treatment of hemophilia A and B. The...
The World Federation of Hemophilia (WFH) 2020 Annual Meeting of the General Assembly was held on October 16, and saw the election of a new...
rHEALTH announced on October 8, 2020 that it was awarded a $1.5 million USD “Direct to Phase II” grant from the National Institutes of Health (NIH)...
In a letter to the global hemophilia community, Roche describes its plan for keeping healthcare professionals and patients informed of new efficacy and safety data...
Update to WFH Notice: Global recall of Octim®/Octostim® desmopressin nasal spray (1.5 mg/ml) by Ferring Pharmaceuticals With ongoing investigation following the mid-July global recall of...
Roche and Genentech have announced an update on measures being taken in relation to the translucent silicon oil and protein particles that were identified in...
A statement was released by BioMarin regarding the status of the U.S. Food and Drug Administration (FDA) approval process for valoctocogene roxaparvovec gene therapy for...
Update to WFH Notice: recall of desmopressin nasal spray by Ferring Pharmaceuticals (July 20, 2020) August 4, 2020 In mid-July, Ferring Pharmaceuticals initiated a voluntary precautionary...
July 20, 2020 The WFH has learned of a voluntary product recall of desmopressin nasal spray by Ferring Pharmaceuticals, due to out of specification results...